Publication | Closed Access

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Biomarker AnalysisMedicinePharmacologyPathologyBronchial NeoplasmImmune Checkpoint InhibitorCancer TreatmentPhase 2OncologyRadiation OncologyLung Cancer